



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Anticipated Classification
Of this Application:
Class _____ Subclass _____

Prior Application:
Exam'r: **Emily M. Le**
Prior Group Art Unit: **1648**

Attorney's
Docket No.:
Enz-64(D3)

FILED BY EXPRESS MAIL

Mail Stop Patent Application
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450



Sir:


This is a request for filing a _____ CONTINUATION _____ X _____ DIVISIONAL _____
CONTINUATION-IN-PART application under _____ X _____ 37 CFR §1.53(b), of
pending prior application Serial No. 10/375,906 filed on February 27, 2003
of _____ llan, et al. _____
Inventor(s)
for

REGULATION OF IMMUNE RESPONSES BY MANIPULATION OF INTERMEDIARY METABOLITE LEVELS

Title of Invention

1. _____ X _____ Enclosed is a copy of the prior application, as originally filed and
an affidavit or declaration verifying it as a true copy.
2. _____ X _____ Small entity status was previously established in a prior
application and is still applicable.

EXPRESS MAIL CERTIFICATE

"Express Mail" Label No. **EV086339685US**
Deposit Date **December 10, 2003**
I hereby certify that this paper and the attachments
herein are being deposited with the United States Postal
Service "Express Mail Post Office to Addressee" service
under 37 CFR 1.10 on the date indicated above and is
addressed to the Commissioner of Patents and
Trademarks, Washington DC 20231.


Ronald C. Fedus
Reg. N . 32,567
DEC 10 2003

Dat

Ilan, et al.

Serial No.: Not Yet Known

(Divisional of S. N. 10/375,906 filed February 27, 2003)

Filed: Herewith

Page: 2 (Request for a Divisional Application Under 37 C.F.R. §1.53(b) -
December 10, 2003)

3. X The filing fee is calculated as follows:

CLAIMS AS FILED, LESS ANY CLAIMS CANCELLED BY AMENDMENT									
					RATE			FEE	
	Number Filed		Number Extra		Small Entity	Other Entity		Small Entity	Other Entity
Total Claims	25	=	5	x	\$ 9	\$ N/A	=	\$ 45	\$ ---
Independent Claims	2	=	0	x	\$ 43	\$ N/A	=	\$ 0	\$ ---
Multiple Dependent Claims Presented: _____ Yes <u> X </u> No					\$135	\$270		\$ --	\$ ---
* If the difference in Col. 1 is less than zero, enter "0" in Col.2						BASIC FEE		\$385	\$ ---
						TOTAL FEE		\$430	\$ ---

4. X The Commissioner is hereby authorized to charge payment of the filing fee as well as the following fees associated with this application or to credit any overpayment to Deposit Account No. 05-1135. A **duplicate** copy of this sheet is enclosed.

 X Any additional filing fees required under 37 CFR §1.16.

 X Any patent application processing fees under 37 CFR §1.17.

5. X The Commissioner is hereby authorized to charge payment of the following fees during the pendency of this application or credit any overpayment to Deposit Account No. 05-1135. A **duplicate** copy of this sheet is enclosed.

 X Any patent application processing fees under 37 CFR §1.17.

 The issue fee set in 37 CFR §1.18 at or before mailing of the Notice of Allowance, pursuant to 37 CFR §1.311(b).

Ilan, et al.

Serial No.: Not Yet Known

(Divisional of S. N. 10/375,906 filed February 27, 2003)

Filed: Herewith

Page: 3 (Request for a Divisional Application Under 37 C.F.R. §1.53(b) -
December 10, 2003)

_____ Any filing fees under 37 CFR §1.16 for
presentation of extra claims.

6. _____ A check in the amount of \$ _____ is enclosed.
7. X Cancel claims 1-24 & 50-62 .
8. X Amend the specification by inserting before the first line of the
sentence: --- This is a _____ continuation, X divisional
of U.S. Patent Application Serial No. 10/375,906, filed on
February 27, 2003.---
9. _____ Transfer the drawings from the prior application.
10. X Informal X Formal _____ drawings are enclosed.
11. _____ Abandon said prior application as of the filing date accorded this
application. A **duplicate** copy of this sheet is enclosed for filing
in the prior application file.
12. _____ Priority of application Serial No. _____ filed on
_____ is claimed under 35 U.S.C. §119.
_____ The certified copy of the priority application has
been filed in prior application Serial No. _____ ,
filed _____.
13. X The prior application is assigned of record to Enzo Therapeutics,
Inc., c/o Enzo Biochem, Inc., 527 Madison Avenue, New York,
New York 10022. A copy of the Assignment is enclosed.
14. _____ A preliminary amendment is enclosed.

Ilan, et al.

Serial No.: Not Yet Known

(Divisional of S. N. 10/375,906 filed February 27, 2003)

Filed: Herewith

Page: 4 (Request for a Divisional Application Under 37 C.F.R. §1.53(b) -
December 10, 2003)

15. X The power of attorney in the prior application is to:
Ronald C. Fedus, Reg. No. 32,567.
- (a) X The power appears in the original papers in the
prior application.
- (b) Since the power does not appear in the original
papers, a copy of the power in the prior application
is enclosed.
- (c) A copy of a new substitute power of attorney is
enclosed.
- (d) A copy of a new Associate Power of Attorney is
enclosed.
- (e) X Address all future communications to: (May only
be completed by applicant, or attorney or agent of
record.)

Ronald C. Fedus, Esq.
Enzo Therapeutics, Inc.
c/o Enzo Biochem, Inc.
527 Madison Avenue (9th Floor)
New York, New York 10022-4304

16. X Oath or Declaration
- (a) Newly executed (original or copy)
- (b) X Copy from a prior application (37 CFR 1.63(d))
- (c) X With Power of Attorney
- (D) Without Power of Attorney

Ilan, et al.

Serial No.: Not Yet Known

(Divisional of S. N. 10/375,906 filed February 27, 2003)

Filed: Herewith


Page: 5 (Request for a Divisional Application Under 37 C.F.R. §1.53(b) -
December 10, 2003)

17. X I hereby verify that the attached papers are a true copy of prior
application Serial No. 10/375,906, filed on February 27, 2003.

The undersigned declares further that all statements made herein of his own
knowledge are true and that all statements made on information and belief are
believed to be true; and further that these statements were made with the
knowledge that willful false statements and the like so made are punishable by fine
or imprisonment, or both, under Section 1001 of Title 18 of the United States Code
and that such willful false statements may jeopardize the validity of the application
or any patent issuing thereon.

December 10, 2003
Date

Respectfully submitted,



Ronald C. Fedus

Registration No. 32,567

Attorney for Applicants

 Inventor(s)

 Assignee of Complete Interest

 X Attorney or Agent of Record

 X Filed under 37 CFR § 1.34(a)

Address of Signator:

Enzo Therapeutics, Inc.

c/o Enzo Biochem, Inc.

527 Madison Avenue (9th Floor)

New York, NY 10022-4304

APPLICATION
FOR
UNITED STATES LETTERS PATENT

To Whom It May Concern:

Be it Known that


Yaron Ilan,
Maya Margalit,
Dean L. Engelhardt and
Elazar Rabbani

have invented certain new and useful improvements in

REGULATION OF IMMUNE RESPONSES
BY MANIPULATION OF INTERMEDIARY METABOLITE LEVELS


of which the following is a full, clear and exact description.

Respectfully submitted,



Ronald C. Fedus
Registration No. 32,567
Attorney for Applicants

c/o ENZO BIOCHEM, INC.
527 Madison Avenue, 9th Floor
New York, New York 10022
Telephone: (212) 583-0100
Facsimile: (212) 583-0150

EXPRESS MAIL CERTIFICATE	
"Express Mail" Label No.	<u>EV115518531US</u>
Deposit Date	<u>February 27, 2003</u>
I hereby certify that this paper and the attachments herein are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R §1.10 on the date indicated above and is addressed to the Commissioner of Patents and Trademarks, Washington DC 20231.	
 Ronald C. Fedus Reg. No. 32,567	<u>FEB 27 2003</u> Date